NCT05456490View on ClinicalTrials.gov

Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions
Healthy
Interventions
DRUG

Liposomal Bupivacaine 13.3

Injection into the Intrathecal space

DRUG

Bupivacaine

Injection into the Intrathecal space

OTHER

Placebo

Injection into the Intrathecal space

Trial Locations (1)

27710

Duke University, Durham

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY